Live feed07:00:00·1303dPRReleasevia QuantisnowAdaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck CancersByQuantisnow·Wall Street's wire, on your screen.ADAP· Adaptimmune Therapeutics plcHealth Care
